Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

Abstract Background Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients. Methods A multicenter, single-arm, hypothesis-driven trial was planned, according to a phase 2 design, to study the e...

Full description

Bibliographic Details
Main Authors: Francesco Perrone, Maria Carmela Piccirillo, Paolo Antonio Ascierto, Carlo Salvarani, Roberto Parrella, Anna Maria Marata, Patrizia Popoli, Laurenzia Ferraris, Massimiliano M. Marrocco-Trischitta, Diego Ripamonti, Francesca Binda, Paolo Bonfanti, Nicola Squillace, Francesco Castelli, Maria Lorenza Muiesan, Miriam Lichtner, Carlo Calzetti, Nicola Duccio Salerno, Luigi Atripaldi, Marco Cascella, Massimo Costantini, Giovanni Dolci, Nicola Cosimo Facciolongo, Fiorentino Fraganza, Marco Massari, Vincenzo Montesarchio, Cristina Mussini, Emanuele Alberto Negri, Gerardo Botti, Claudia Cardone, Piera Gargiulo, Adriano Gravina, Clorinda Schettino, Laura Arenare, Paolo Chiodini, Ciro Gallo, the TOCIVID-19 investigators, Italy
Format: Article
Language:English
Published: BMC 2020-10-01
Series:Journal of Translational Medicine
Subjects:
COVID-19
Pneumonia
Coronavirus
Tocilizumab
IL-6
Phase 2
Online Access:http://link.springer.com/article/10.1186/s12967-020-02573-9

Internet

http://link.springer.com/article/10.1186/s12967-020-02573-9

Similar Items